REDOX POTENTIAL AND OXYGEN CONCENTRATION AS FACTORS IN THE SUSCEPTIBILITY OF HELICOBACTER-PYLORI TO NITROHETEROCYCLIC DRUGS

被引：68

作者：

SMITH, MA ^{[1
]}

EDWARDS, DI ^{[1
]}

机构：

[1] UNIV E LONDON, CHEMOTHERAPY RES UNIT, LONDON E15 4LZ, ENGLAND

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 1995年 / 35卷 / 06期

关键词：

D O I：

10.1093/jac/35.6.751

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Metronidazole sensitive (Mtz(S)) and resistant (Mtz(R)) strains of Helicobacter pylori were tested for their sensitivities to eleven nitroheterocyclic drugs of known reduction potential under a wide range of environmental conditions. Under microaerophilic conditions, Mtz(R) strains were sensitive to all the 2-nitroimidazoles, resistant to every 5-nitroimidazole, and slightly sensitive to the nitrothiazole, niridazole. Mtz(S) strains were sensitive to all the nitroimidazoles except for 4(5)-nitroimidazole which has the lowest redox potential of all the drugs investigated. Mtz(S) strains displayed the greatest sensitivity towards niridazole and satranidazole, the latter having the highest redox potential of the 5-nitroimidazoles. High and low oxygen tensions had no effect on the activity of the drugs but periods of anaerobic incubation caused resistant strains to become sensitive to the 5-nitroimidazoles. Superoxide dismutase and catalase were not induced by metronidazole and enzyme levels showed no correlation with resistance patterns. The results show that futile cycling does not occur in H. pylori and that the mechanism of action of the nitroimidazoles is related to their redox potential. Anaerobiosis abolishes resistance to metronidazole which suggests that it may be mediated through the activation of anaerobic metabolic pathways which function less under microaerophilic conditions or not at all.

引用

页码：751 / 764

页数：14

共 35 条

[11]

Edwards D.I., Dye M., Carne H., The selective toxicity of antimicrobial nitroheterocyclic drugs, Journal of General Microbiology, 76, pp. 135-145, (1973)

[12]

Edwards D.I., Tocher J.H., Dale L.D., Widdick D.A., Virk N.S., Effect on DNA of bioreducible nitroimidazoleand benzotriazine drugs, Selective Activation of Drugs by Redox Processes, pp. 275-283, (1990)

[13]

An international association between Helicobacter pylori infection and gastric cancer, Lancet, 341, pp. 1359-1362, (1993)

[14]

Forman D., Newell D.G., Fullerton F., Yamell J.W.D., Stacey A.R., Wald N., Et al., Association between infection with Helicobacter pylori and the risk of gastric cancer: Evidence from a prospective investigation, British Medical Journal, 302, pp. 1302-1305, (1991)

[15]

George L.L., Borody T.J., Rews P., Derme M., Moore-Jones D., Walton M., Et al., Cure of duodenal ulcer after eradication of Helicobacter pylori, Medical Journal of Australia, 153, pp. 145-149, (1990)

[16]

Graham D.Y., Lew G.M., Kleine P.D., Evans D.G., Evans D.J., Saeed Z.A., Et al., Results of treatment of Helicobacter pylori infection on the recurrence of gastric or duodenal ulcers: A randomized single-blind, single center study, Gastroenterology, 100, (1991)

[17]

Halliwell B., Gutteridge J.M.C., Free Radicals in Biology and Medicine, (1989)

[18]

Hof H., Sticht-Groh V., Muller K.-M., Comparative in vitro activities of niridazole and metronidazole against anaerobic and microaerophilic bacteria, Antimicrobial Agents and Chemotherapy, 22, pp. 332-333, (1982)

[19]

Lloyd D., Yarlett N., Yarlett N.C., Patterson J.Z., Kristensen B., Metronidazole-resistant clinical isolates of Trichomonas vaginalis maintain low intracellular radical anion levels as a consequence of defective oxygen scavenging, Acta Universitatis Carolinae-Biologica, 30, pp. 521-528, (1986)

[20]

Logan L.P.H., Gummet P.A., Misiewicz J.J., Karim Q.N., Walker M.M., Baron G.H., One week eradication regime for Helicobacter pylori, Lancet Ii, pp. 1449-1452, (1991)

← 1 2 3 4 →